RECOMBINANT DNA TECHNOLOGY IN THERAPEUTIC DEVELOPMENT: A MOLECULAR APPROACH
DOI:
https://doi.org/10.4238/cz02gy87Keywords:
Recombinant DNA technology; therapeutic development; recombinant vector; molecular cloning; recombinant expression.Abstract
Recombinant DNA technology is a central molecular approach for therapeutic development through controlled gene manipulation, cloning, and expression of selected genetic sequences. This approach supports the production of recombinant proteins, enzymes, vaccines, antibodies, and gene-based therapeutic molecules with improved specificity and reproducibility. The objective of this study was to evaluate recombinant DNA technology as a platform for therapeutic development through target-gene selection, recombinant construct design, molecular confirmation, expression assessment, and preliminary functional evaluation. A therapeutically relevant coding sequence was selected and analyzed for open reading frame integrity, nucleotide composition, codon compatibility, restriction-site suitability, and predicted protein features. A compatible recombinant vector was designed, followed by host-cell transformation, colony screening, plasmid analysis, restriction digestion, and sequence verification. Recombinant expression was assessed using suitable molecular or biochemical methods, followed by preliminary functional assays to examine biological activity, binding response, and cellular compatibility. Results showed that the selected target sequence had suitable molecular characteristics for recombinant development. Construct analysis indicated acceptable vector-insert compatibility and expression-related potential. Molecular screening confirmed recombinant clone formation, while expression analysis showed detectable recombinant product formation with moderate yield and partial purification. Preliminary functional assessment indicated measurable biological activity and acceptable cellular response within the tested range. Recombinant DNA technology, therefore, provides a structured molecular route for early therapeutic development. Further optimization, biosafety evaluation, stability testing, and preclinical validation remain necessary before translational application.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

